Program
zasocitinib
Also written as “Zasocitinib”, “TAK-279” and “NDI-034858 study drug”.
Its studies are mostly in Psoriasis · Arthritis, Psoriatic · Crohn Disease · Hidradenitis Suppurativa · Vitiligo, led by Takeda.
Drug pageZasocitinib: every studyAll 26 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takeda | 2613 open or running | phase 3since Oct 12, 2023 | Jul 19, 2021 | Feb 5, 2027phase 2 · NCT07244263 |
Also a collaborator on its studies: Nimbus Lakshmi.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 12 earlier studies, Jul 19, 2021 to Feb 6, 2024.
- Jan 19, 2023Named zasocitinibINNProposed as its International Nonproprietary Name in WHO's List 128 · before, TAK-279, NDI-034858
- Mar 15, 2024Phase 3 study in PsoriasisNCT06323356 · 18 enrolled · Japan
- Aug 8, 2024Phase 3 study in Plaque PsoriasisNCT06550076 · 2,099 enrolled · United States, Argentina, Australia and more
- Oct 31, 20242 phase 3 studies in Arthritis, PsoriaticNCT06671496, NCT06671483
- Jan 2, 2025Phase 2 study in Crohn DiseaseNCT06764615 · 192 planned · United States, China, Czechia and more
- Jan 21, 2025Phase 1 study in Healthy VolunteersNCT06793943 · 78 enrolled · United States
- May 8, 2025Phase 3 study in Plaque PsoriasisNCT06973291 · 606 enrolled · United States, Bulgaria, Canada and more
- Aug 5, 2025Phase 2 study in Nonsegmental VitiligoNCT07108283 · 207 enrolled · United States, Canada, China and more
- Nov 17, 2025Phase 2 study in Hidradenitis SuppurativaNCT07244263 · 91 enrolled · United States, Australia, Canada and more
- Nov 18, 2025Phase 3 study in Plaque PsoriasisNCT07250802 · 210 planned · United States, China, Germany and more
- Dec 11, 2025Phase 3 study in Arthritis, PsoriaticNCT07286058 · 1,182 planned · United States, Argentina, Australia and more
- Feb 4, 2026Phase 2 study in Crohn DiseaseNCT07403968 · 20 planned · United Kingdom
- Aug 4, 2026Phase 3 study in PsoriasisNCT07752108 · 40 planned
- Oct 7, 2026Phase 3 study in Arthritis, PsoriaticNCT07871721 · 644 planned
- Nov 16, 2026Primary completion moved from 2033-01-24 to 2034-07-03Date moved laterphase 3 · +17 months · NCT07250802
Ahead
- Feb 5, 2027Primary completion: phase 2 study in Hidradenitis SuppurativaNCT07244263
- Feb 17, 2027Primary completion: phase 2 study in Crohn DiseaseNCT06233461
- Mar 26, 2027Primary completion: phase 2 study in Nonsegmental VitiligoNCT07108283
- May 18, 2027Primary completion: phase 3 study in Arthritis, PsoriaticNCT06671496
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 26 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07871721Arthritis, Psoriatic | 3 | Not yet recruiting | Apr 18, 2030 | 644 |
| NCT07752108Psoriasis | 3 | Not yet recruiting | May 30, 2027 | 40 |
| NCT07403968Crohn Disease · United Kingdom | 2 | Recruiting | Mar 30, 2028 | 20 |
| NCT07286058Arthritis, Psoriatic · United States, Argentina, Australia and more | 3 | Recruiting | Dec 18, 2029 | 1,182 |
| NCT07250802Plaque Psoriasis · United States, China, Germany and more | 3 | Recruiting | Jul 3, 2034 | 210 |
| NCT07244263Hidradenitis Suppurativa · United States, Australia, Canada and more | 2 | Active, not recruiting | Feb 5, 2027 | 91 |
| NCT07108283Nonsegmental Vitiligo · United States, Canada, China and more | 2 | Active, not recruiting | Mar 26, 2027 | 207 |
| NCT06973291Plaque Psoriasis · United States, Bulgaria, Canada and more | 3 | Completed | Apr 22, 2026 | 606 |
| NCT06793943Healthy Volunteers · United States | 1 | Completed | Mar 11, 2025 | 78 |
| NCT06764615Crohn Disease · United States, China, Czechia and more | 2 | Recruiting | Dec 30, 2029 | 192 |
| NCT06671496Arthritis, Psoriatic · United States, Argentina, Australia and more | 3 | Active, not recruiting | May 18, 2027 | 601 |
| NCT06671483Arthritis, Psoriatic · United States, Belgium, Bulgaria and more | 3 | Active, not recruiting | May 18, 2027 | 1,583 |
| NCT06550076Plaque Psoriasis · United States, Argentina, Australia and more | 3 | Active, not recruiting | Aug 5, 2029 | 2,099 |
| NCT06323356Psoriasis · Japan | 3 | Completed | Oct 17, 2025 | 18 |
| NCT06290050Healthy Volunteers · United States | 1 | Completed | May 3, 2024 | 20 |
| NCT06258265Healthy Volunteers · United States | 1 | Completed | Jun 25, 2024 | 120 |
| NCT06254950Colitis, Ulcerative · United States, Australia, Belgium and more | 2 | Active, not recruiting | Jul 14, 2026 | 213 |
| NCT06233461Crohn Disease · United States, Australia, Belgium and more | 2 | Recruiting | Feb 17, 2027 | 268 |
| NCT06111547Healthy Volunteers · China | 1 | Completed | Jul 23, 2024 | 24 |
| NCT06108544Plaque Psoriasis · United States, Argentina, Bulgaria and more | 3 | Completed | Dec 6, 2024 | 1,108 |
| NCT06088043Plaque Psoriasis · United States, Australia, Canada and more | 3 | Completed | Jan 22, 2025 | 693 |
| NCT05995249Healthy Volunteers · United States | 1 | Completed | Dec 18, 2023 | 172 |
| NCT05992155Renal Insufficiency · United States | 1 | Completed | May 22, 2024 | 24 |
| NCT05976321Hepatic Impairment · United States | 1 | Completed | Apr 15, 2024 | 27 |
| NCT05153148Arthritis, Psoriatic · United States, Czechia, Germany and more | 2 | Completed | May 4, 2023 | 305 |
| NCT04999839Moderate to Severe Plaque Psoriasis · United States, Canada | 2 | Completed | Aug 19, 2022 | 259 |
How it is read
Names in the registry
- “Zasocitinib”, 12 entries
- “TAK-279”, 12 entries
- “NDI-034858 study drug”, 4 entries
- “Zasocitinib (Dose A)”, 1 entry
- “NDI-034858”, 1 entry
Conditions, from the studies’ own filings
- Psoriasis, 8 studies
- Arthritis, Psoriatic, 5 studies
- Crohn Disease, 3 studies
- Hidradenitis Suppurativa, 1 study
- Vitiligo, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.